Data / Research funding / Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS): 300 NIH awards ($684.3M) to 107 organizations
300 NIH awards ($684.3M) in the NIH spending category Amyotrophic Lateral Sclerosis (ALS), to 107 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
300 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Access for All in ALS (ALL ALS) West Clinical Coordinating Center | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $51,203,440 | September 25, 2023 | June 30, 2027 | BOWSER, ROBERT P | reporter.nih.gov |
| Access for All in ALS (ALL ALS) East Clinical Coordinating Center | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $49,098,369 | September 25, 2023 | June 30, 2027 | BERRY, JAMES DALE | reporter.nih.gov |
| Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $33,014,143 | September 25, 2023 | April 30, 2027 | BERRY, JAMES DALE | reporter.nih.gov |
| An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Pridopidine | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $27,895,551 | September 25, 2023 | August 31, 2027 | PAGANONI, SABRINA | reporter.nih.gov |
| Intermediate-sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS). | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $22,785,879 | September 25, 2023 | August 31, 2027 | ANDREWS, JINSY | reporter.nih.gov |
| Admin. Supp.: Correction of Neurological Disease via Allele Specific Excision of Pathogenic Repeats | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $13,703,967 | May 15, 2023 | April 30, 2028 | DOUDNA, JENNIFER A | reporter.nih.gov |
| Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS (SEA-NOBI-ALS) | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $11,846,278 | September 1, 2024 | August 31, 2028 | OSKARSSON, BJORN E | reporter.nih.gov |
| Intermediate-sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS). | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $11,639,047 | September 25, 2023 | August 31, 2027 | ANDREWS, JINSY | reporter.nih.gov |
| Pre-Symptomatic Familial ALS (Pre-fALS) Study: From Prodrome and Biomarkers to ALS/FTD Prevention | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $11,282,768 | September 15, 2018 | July 31, 2029 | BENATAR, MICHAEL | reporter.nih.gov |
| Silence ALS: A Platform for the Discovery and Development of Antisense Therapeutics for Patients with Ultra-Rare Forms of ALS | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $9,796,602 | March 1, 2024 | February 28, 2027 | SHNEIDER, NEIL ALAN | reporter.nih.gov |
| Identification of TDP-43 Modifiers Through Single-Cell Transcriptional and Epigenomic Dissection of ALS and FTLD-MND | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $9,106,321 | September 29, 2021 | August 31, 2026 | DONNELLY, CHRISTOPHER JAMES | reporter.nih.gov |
| The Physical Biology of Neurodegeneration in Sporadic Amyotrophic Lateral Sclerosis/Frontotemporal Dementia | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $8,227,499 | September 1, 2021 | August 31, 2027 | PHATNANI, HEMALI | reporter.nih.gov |
| Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders | NIH | National Institute on Aging | 2021 to 2025 | $7,375,647 | July 1, 2021 | December 31, 2026 | REITZ, ALLEN BERNARD | reporter.nih.gov |
| SWITCH Trial: Early Feasibility Study of Stentrode BCI for Augmentative Communication | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $5,728,624 | August 15, 2021 | July 31, 2027 | WEBER, DOUGLAS J | reporter.nih.gov |
| Targeting Dysregulated RNA Splicing in Neurodegenerative Diseases | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $5,093,143 | September 1, 2023 | August 31, 2028 | LAGIER-TOURENNE, CLOTILDE | reporter.nih.gov |
| Leveraging Natural Phenotypic Variations of Heterogenous ALS Populations-in-a-Dish to Enable Scalable Drug Discovery | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $4,949,698 | September 18, 2022 | August 31, 2027 | ICHIDA, JUSTIN KAWIKA | reporter.nih.gov |
| Investigation of the Cortical Communication (CORTICOM) System | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $4,646,011 | September 15, 2020 | December 31, 2025 | CRONE, NATHAN E | reporter.nih.gov |
| Single-neuron population dynamics in human speech motor cortex for a speech prosthesis | NIH | National Institute on Deafness and Other Communication Disorders | 2021 to 2025 | $4,390,591 | August 2, 2021 | July 31, 2027 | HENDERSON, JAIMIE M | reporter.nih.gov |
| Innovating Yeast and Human Genetics Approaches to Define Mechanisms of Neurodegenerative Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $4,359,590 | December 1, 2016 | November 30, 2024 | GITLER, AARON D. | reporter.nih.gov |
| Microglia contribution to disease pathogenesis in C9orf72 ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $4,229,195 | September 1, 2021 | August 31, 2027 | SATTLER, RITA | reporter.nih.gov |
| Optimization of an in vivo base editing strategy to treat SOD1-linked ALS | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $4,091,010 | July 25, 2025 | November 30, 2026 | GAJ, THOMAS | reporter.nih.gov |
| Evaluation of a novel NLK function in lysosome biogenesis and neurodegenerative diseases | NIH | National Institute on Aging | 2021 to 2025 | $4,024,826 | August 1, 2021 | October 31, 2026 | LIM, JANGHOO | reporter.nih.gov |
| Nuclear pore complex quality control in ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $4,005,112 | May 1, 2021 | April 30, 2026 | ROTHSTEIN, JEFFREY D | reporter.nih.gov |
| Regulation of mRNA processing: Mechanisms and Consequences | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,993,090 | June 8, 2016 | May 31, 2026 | MANLEY, JAMES L. | reporter.nih.gov |
| Frontotemporal dementia and related disorders: transcriptomic profiling, biomarker discovery, and mechanistic insight | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,904,675 | April 15, 2021 | March 31, 2027 | VAN BLITTERSWIJK, MARKA | reporter.nih.gov |
| TDP-43 acetylation, phase separation, aggregation, and clearance by antibody-mediated degradation | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,806,187 | April 1, 2021 | March 31, 2026 | CLEVELAND, DON W | reporter.nih.gov |
| Circular RNAs and their interactions with RNA-binding proteins to modulate AD-related neuropathology | NIH | National Institute on Aging | 2021 to 2025 | $3,774,499 | July 1, 2021 | June 30, 2027 | ZHANG, XIAOLING | reporter.nih.gov |
| Role of the Intestinal Microbiota in ALS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,664,593 | January 15, 2021 | December 31, 2025 | WEINER, HOWARD L | reporter.nih.gov |
| Single-Cell Transcriptional and Epigenomic Dissection to Identify Therapeutic Targets for ALS and FTD | NIH | National Institute on Aging | 2021 to 2025 | $3,657,244 | March 1, 2021 | November 30, 2026 | KELLIS, MANOLIS | reporter.nih.gov |
| Nuclear and Glial Dysfunction in Neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $3,647,532 | May 16, 2023 | April 30, 2031 | ROTHSTEIN, JEFFREY D | reporter.nih.gov |
| Polyalanine Tails: A Novel Type of Protein Modification Implicated in Neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,598,452 | August 1, 2017 | May 31, 2027 | BURGESS, ROBERT W. | reporter.nih.gov |
| Intuitive, complete neural control of tablet computers for communication | NIH | National Institute on Deafness and Other Communication Disorders | 2021 to 2025 | $3,478,840 | April 1, 2019 | June 30, 2027 | HOCHBERG, LEIGH R | reporter.nih.gov |
| Developing novel strategies for personalized treatment and prevention of ALS: Leveraging the global exposome, genome, epigenome, metabolome, and inflammasome with data science in a case/control cohort | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $3,429,869 | September 30, 2021 | June 30, 2026 | FELDMAN, EVA LUCILLE | reporter.nih.gov |
| Corticospinal Neuron Dysfunction and Degeneration in ALS: Testing the Role of Corticomotor Connectivity in Motor Neuron Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,399,326 | December 1, 2020 | November 30, 2025 | YOSHIDA, YUTAKA | reporter.nih.gov |
| Protein aggregation in inclusion body and myofibrillar myopathies | NIH | National Institute on Aging | 2021 to 2025 | $3,388,405 | January 1, 2009 | March 31, 2029 | WEIHL, CONRAD C | reporter.nih.gov |
| Defining short RNA therapeutics that combat TDP-43 proteinopathy connected to AD and ADRDs. | NIH | National Institute on Aging | 2025 | $3,360,074 | September 15, 2025 | August 31, 2029 | SHORTER, JAMES | reporter.nih.gov |
| Regulation mechanism and functional genomics of LINE1 RNA in TDP-43 linked neurodegeneration | NIH | National Institute on Aging | 2022 to 2025 | $3,349,668 | September 15, 2022 | May 31, 2027 | SUN, SHUYING | reporter.nih.gov |
| Investigating aberrant vesicular degradation and lipid metabolism in neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $3,323,710 | August 15, 2025 | July 31, 2029 | BOSCO, DARYL ANGELA | reporter.nih.gov |
| DIrectional and SCalable (DISC) Microelectrode Array for Speech Decoding | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $3,269,286 | February 1, 2023 | January 31, 2027 | SEYMOUR, JOHN P | reporter.nih.gov |
| Investigating Dysregulation of Stress-related Ribonucleoprotein Granules and Functions of Associated RNA-binding Proteins in ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,254,207 | February 1, 2019 | November 30, 2028 | WANG, JIOU | reporter.nih.gov |
| Multi-Targeting Oligonucleotide Therapeutics for Familial and Sporadic Amyotrophic Lateral Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,236,744 | May 15, 2019 | May 31, 2029 | WATTS, JONATHAN K | reporter.nih.gov |
| Investigating the role of TMEM106b genetics and pathology in Alzheimer’s disease, LATE and FTLD | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $3,221,644 | September 22, 2023 | August 31, 2028 | PETRUCELLI, LEONARD | reporter.nih.gov |
| Characterization of Antigen-Specific Immune Response in ALS | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $3,213,011 | August 11, 2025 | July 31, 2029 | ELYAMAN, WASSIM | reporter.nih.gov |
| Genetic Contributions to Phenotypic Heterogeneity in the ALS-FTD Spectrum | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $3,204,260 | August 1, 2025 | July 31, 2029 | MCMILLAN, COREY T | reporter.nih.gov |
| Upstream pathogenesis in familial and sporadic frontotemporal dementia and motor neuron disease | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $3,153,019 | July 1, 2018 | July 31, 2029 | SEELEY, WILLIAM W | reporter.nih.gov |
| Integrating the exposome and epigenome identifies determinants of ALS risk, survival, and pathogenesis | NIH | National Institute of Environmental Health Sciences | 2025 | $3,133,754 | September 10, 2025 | September 9, 2029 | FELDMAN, EVA LUCILLE | reporter.nih.gov |
| Understanding the sequence and structural determinants of phase behavior of ALS-causing proteins | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $3,121,003 | February 1, 2021 | January 31, 2027 | MITTAG, TANJA | reporter.nih.gov |
| Integrating Spatial Multi-omics and Clinical Covariates to Identify Mechanisms of Disease in ALS-FTD | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $3,108,178 | August 15, 2020 | April 30, 2026 | PHATNANI, HEMALI | reporter.nih.gov |
| Single molecule study of C9ORF72 repeat RNA metabolisms in ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $3,085,325 | March 1, 2020 | May 31, 2029 | SUN, SHUYING | reporter.nih.gov |
| Mechanism of ALS/FTD determined by multimodal single cell spatial transcriptomics | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $3,081,936 | September 12, 2025 | June 30, 2029 | CLEVELAND, DON W | reporter.nih.gov |
| Disease Mechanism and Therapy in TDP-43 Proteinopathies and Dementias | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $3,081,573 | April 1, 1989 | August 31, 2027 | CLEVELAND, DON W | reporter.nih.gov |
| Molecular Genetic Insight into Neurodegenerative Disease from Drosophila | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $3,032,672 | December 1, 2016 | November 30, 2025 | BONINI, NANCY M | reporter.nih.gov |
| Feedback amplification between Retrotransposons/endogenous retroviruses and TDP-43 in Alzheimers related dementias | NIH | National Institute on Aging | 2022 to 2025 | $3,027,350 | September 15, 2022 | June 30, 2027 | DUBNAU, JOSHUA T | reporter.nih.gov |
| Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,974,321 | May 15, 2021 | February 28, 2027 | GOUTMAN, STEPHEN | reporter.nih.gov |
| Intermuscular coherence: A novel biomarker for upper motor neuron dysfunction in ALS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,960,779 | January 1, 2021 | December 31, 2026 | REZANIA, KOUROSH | reporter.nih.gov |
| Investigating the Novel Disease Pathways Associated with C9orf72-Linked ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,951,882 | May 15, 2015 | April 30, 2030 | WANG, JIOU | reporter.nih.gov |
| Functional and Pathological Interactions of TDP-43 | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,925,557 | April 1, 2020 | March 31, 2025 | FAWZI, NICOLAS LUX | reporter.nih.gov |
| Defining mechanisms underlying C9orf72-associated frontotemporal dementia with C. elegans and mammalian models | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,904,236 | February 1, 2022 | January 31, 2027 | KALB, ROBERT G | reporter.nih.gov |
| Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD | NIH | National Institute on Aging | 2023 to 2024 | $2,894,619 | August 1, 2023 | July 31, 2025 | ALWORTH, SAMUEL V | reporter.nih.gov |
| Mapping the ALS Exposome to Gain New Insights into Disease Risk and Pathogenesis | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $2,877,528 | January 1, 2020 | October 31, 2024 | FELDMAN, EVA LUCILLE | reporter.nih.gov |
| SARM1 functional polymorphisms and their contribution to ALS risk | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,868,750 | January 1, 2021 | December 31, 2025 | BLOOM, ADAM JOSEPH | reporter.nih.gov |
| Investigation of the role of ATXN1 in oligodendroglia and neurodegenerative diseases | NIH | National Institute on Aging | 2022 to 2025 | $2,847,875 | March 1, 2022 | December 31, 2026 | LIM, JANGHOO | reporter.nih.gov |
| The role of a metazoan-specific PQC system in protecting against TDP-43 proteinopathies | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $2,817,215 | August 7, 2025 | July 31, 2029 | YANG, XIAOLU | reporter.nih.gov |
| Validating Secretory Autophagy as a Therapeutic Strategy for Diverse Forms of ALS and FTD | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,714,836 | July 1, 2017 | June 30, 2026 | ICHIDA, JUSTIN KAWIKA | reporter.nih.gov |
| Role of TRIM11 in regulating TDP-43 and FUS | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $2,709,695 | September 5, 2025 | August 31, 2029 | YANG, XIAOLU | reporter.nih.gov |
| Expanding the Chemical Diversity of Therapeutic Oligonucleotides | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,703,592 | September 25, 2017 | March 31, 2028 | KHVOROVA, ANASTASIA | reporter.nih.gov |
| Development of an UNC13A antisense oligonucleotide treatment for ALS and FTD | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $2,670,896 | August 1, 2023 | July 31, 2025 | CHANG, WEN-HSUAN | reporter.nih.gov |
| Mechanisms of Novel Regulators of Proteotoxicity and Quality Control Associated with ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,659,547 | August 15, 2011 | February 28, 2027 | WANG, JIOU | reporter.nih.gov |
| TDP-43 in Alzheimer's disease | NIH | National Institute on Aging | 2021 to 2025 | $2,612,954 | September 1, 2021 | May 31, 2027 | LIACHKO, NICOLE FARON | reporter.nih.gov |
| Spinal Subpial Gene Delivery for Treatment of Amyotrophic Lateral Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,547,168 | September 28, 2022 | July 31, 2027 | MARSALA, MARTIN | reporter.nih.gov |
| Brain-derived extracellular vesicles as a novel source of biomarkers for disease progression and environmental exposure in ALS | NIH | National Institute of Environmental Health Sciences | 2021 to 2024 | $2,546,474 | February 1, 2020 | October 31, 2025 | RE, DIANE BERENGERE | reporter.nih.gov |
| Investigating Pathogenic Mechanisms of Frontotemporal Dementia Caused by Mutations in CHMP2B and TBK1 | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,537,267 | January 1, 2018 | November 30, 2025 | GAO, FEN-BIAO | reporter.nih.gov |
| Molecular Basis of Pathogenic Cascades in ALS/FTD Initiated from C9orf72 Hexanucleotide Repeat Expansion | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,469,291 | July 15, 2022 | May 31, 2027 | WANG, JIOU | reporter.nih.gov |
| RNA-based regulation of TDP-43 nuclear export in ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,447,618 | August 1, 2021 | June 30, 2026 | HOKE, AHMET | reporter.nih.gov |
| Biochemical and molecular heterogeneity of human TDP-43 proteinopathies in age-related dementias | NIH | National Institute on Aging | 2022 to 2025 | $2,424,308 | July 15, 2022 | April 30, 2027 | PORTA ANTOLINEZ, SILVIA | reporter.nih.gov |
| Protein Arginine Deiminase 2 (PAD2) and Protein Citrullination in ALS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,423,685 | July 1, 2021 | April 30, 2027 | XU, ZUOSHANG | reporter.nih.gov |
| TMEM106B in neurodegenerative disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,390,842 | July 15, 2013 | February 28, 2025 | CHEN-PLOTKIN, ALICE S | reporter.nih.gov |
| Poly(ADP-ribose) promotes the condensation and toxicity of C9orf72 arginine-rich dipeptide repeat proteins | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,345,590 | July 15, 2021 | June 30, 2027 | ZHANG, YONGJIE | reporter.nih.gov |
| Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS) | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $2,309,830 | September 19, 2023 | August 31, 2026 | MURAD, JOANA M | reporter.nih.gov |
| A digital tool for monitoring speech decline in ALS | NIH | National Institute on Deafness and Other Communication Disorders | 2022 to 2024 | $2,307,774 | June 1, 2022 | May 31, 2026 | GREEN, JORDAN R | reporter.nih.gov |
| Investigating the Contribution of ALS/FTD-Associated Mutations in the NEK1 Kinase to Disease Pathophysiology | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $2,276,048 | July 15, 2023 | April 30, 2028 | KISKINIS, EVANGELOS | reporter.nih.gov |
| Excitability Dysfunction Mechanisms Underlying the TDP43-Dependent ALS and FTD Pathogenesis | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $2,264,232 | August 1, 2023 | July 31, 2028 | ELBASIOUNY, SHERIF M | reporter.nih.gov |
| Spatially Resolved Dynamics of Molecular Pathology and Intercellular Interactions in Amytrophic Lateral Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,228,134 | February 1, 2020 | January 31, 2026 | PHATNANI, HEMALI | reporter.nih.gov |
| Illuminating cellular dark matter through the development of novel chemical tools | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,223,484 | July 1, 2021 | June 30, 2026 | DEVARAJ, NEAL KRISHNA | reporter.nih.gov |
| A microphysiologic multicellular organ-on-chip to inform clinical trials in FTD/ALS | NIH | National Center for Advancing Translational Sciences | 2022 to 2024 | $2,198,065 | July 1, 2020 | November 30, 2025 | SVENDSEN, CLIVE NIELS | reporter.nih.gov |
| Blood-based Biomarker for Characterizing Progression and Therapeutic Response in Amyotrophic Lateral Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $2,147,016 | September 1, 2024 | August 31, 2026 | EITAN, EREZ | reporter.nih.gov |
| RNA Surveillance and Protein Translation in FTD | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,139,216 | August 1, 2021 | July 31, 2026 | ZHU, HAINING | reporter.nih.gov |
| Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS | NIH | National Institute on Aging | 2023 to 2025 | $2,130,126 | December 1, 2022 | November 30, 2027 | ROSSOLL, WILFRIED | reporter.nih.gov |
| Mechanisms Underlying Excitability Regulation of Motoneuron Types in ALS | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $2,129,614 | February 1, 2015 | January 31, 2027 | ELBASIOUNY, SHERIF M | reporter.nih.gov |
| Targeting the EphA4 in motor neuron disease: a structure-based approach | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,089,187 | July 1, 2018 | April 30, 2028 | PELLECCHIA, MAURIZIO | reporter.nih.gov |
| Impact of ALS-linked mutations on the structure, dynamics and function of profilin-1 | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $2,070,914 | January 8, 2021 | November 30, 2024 | MASSI, FRANCESCA | reporter.nih.gov |
| Role of Ataxin-2 polyglutamine expansion on TDP-43 transport and post-transcriptional RNA regulation in neurons | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,057,651 | July 15, 2021 | June 30, 2027 | GOPAL, PALLAVI P. | reporter.nih.gov |
| Investigating the role of TDP-43 mislocalization, structure, and post-translational modifications in the neuropathologically heterogeneous TDP-43 proteinopathies | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $2,010,088 | April 16, 2024 | March 31, 2029 | NEWELL, KATHY L | reporter.nih.gov |
| Pathological Signatures of CHCHD10 Dysfunction in ADRDs | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $2,000,425 | August 1, 2021 | June 30, 2027 | KANG, DAVID E | reporter.nih.gov |
| RAD23 Control of ALS phenotypes | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,986,750 | June 1, 2021 | May 31, 2026 | KALB, ROBERT G | reporter.nih.gov |
| Hexanucleotide repeat translation in ALS and Frontotemporal Dementia | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,976,676 | September 1, 2016 | March 31, 2028 | TODD, PETER K | reporter.nih.gov |
| Raloxifene-Based Therapy in Neuro Degenerative Diseases | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,965,858 | December 1, 2020 | November 30, 2025 | GERMAIN, DORIS A | reporter.nih.gov |
| Yeast as a gateway to conquering protein misfolding diseases. | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,954,359 | April 1, 2020 | February 28, 2026 | LIEBMAN, SUSAN W | reporter.nih.gov |
| The role of m6A RNA methylation in C9ORF72-ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $1,953,392 | September 23, 2024 | April 30, 2025 | SUN, SHUYING | reporter.nih.gov |
| Epigenetic Mechanisms Contributing to the Pathogenesis of ALS/FTD with GGGGCC Repeat Expansion Mutation at the C9orf72 Locus | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,949,974 | July 15, 2022 | June 30, 2027 | LIU, X. SHAWN | reporter.nih.gov |
| T cell Immunity in a Rare Juvenile Form of Motor Neuron Disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,919,203 | September 1, 2023 | August 31, 2028 | MARAZZI, IVAN | reporter.nih.gov |
| Multifaceted role of MG53 in alleviating neuromuscular function decline in ALS | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,918,877 | July 1, 2023 | June 30, 2028 | ZHOU, JINGSONG | reporter.nih.gov |
| RNA decay in amyotrophic lateral sclerosis and frontotemporal lobar degeneration | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,900,827 | August 1, 2016 | April 30, 2026 | BARMADA, SAMI | reporter.nih.gov |
| Role of FABP7 in ALS models | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,898,987 | July 1, 2021 | April 30, 2027 | VARGAS, MARCELO R | reporter.nih.gov |
| Defining the Mechanisms and Consequences of Nuclear Defects in ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,888,756 | April 1, 2021 | March 31, 2027 | FALLINI, CLAUDIA | reporter.nih.gov |
| Homeostatic Reset as a New Therapeutic Paradigm for Slow Progression Diseases | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,865,363 | September 15, 2021 | August 31, 2027 | LU, QUN | reporter.nih.gov |
| Determine the neurotoxicity of RNA metabolism dysfunction caused by cytoplasmic TDP-43 aggregates | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,859,204 | September 19, 2023 | August 31, 2028 | SHAHMORADIAN, SARAH H | reporter.nih.gov |
| Pathogenesis and motor neuron degeneration of a novel disease associated with a P158A mutation in NAMPT | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,826,814 | February 15, 2022 | December 31, 2026 | DING, SHINGHUA | reporter.nih.gov |
| Compromised LDH activity causes motor deficits and hastens ALS progression | NIH | National Institute on Aging | 2023 to 2025 | $1,805,312 | July 1, 1996 | January 31, 2028 | MILBRANDT, JEFFREY D | reporter.nih.gov |
| Investigation of UBQLN2 in neuronal dysfunction and ALS-FTD | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,803,720 | June 15, 2023 | May 31, 2028 | WHITELEY, ALEXANDRA | reporter.nih.gov |
| Regulation and impact of shortened TDP43 isoforms in FTD and ALS | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $1,794,354 | December 1, 2019 | August 31, 2029 | BARMADA, SAMI | reporter.nih.gov |
| Defining Immune Cell Heterogeneity in Human ALS and Mouse Model of the Disease | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,775,238 | May 15, 2020 | April 30, 2026 | PRZEDBORSKI, SERGE E | reporter.nih.gov |
| Acoustic Tweezing Cytometry for Efficient Neural Differentiation | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,764,828 | September 22, 2021 | July 31, 2025 | FU, JIANPING | reporter.nih.gov |
| Mechanisms of impaired ESCRT-III nuclear surveillance in ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,736,889 | August 1, 2023 | May 31, 2028 | COYNE, ALYSSA | reporter.nih.gov |
| Mechanistic analysis of TDP-43-mediated RNA localization in neurons and its misregulation in ALS | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,734,380 | September 19, 2023 | August 31, 2028 | TALIAFERRO, JEFFERSON MATTHEW | reporter.nih.gov |
| A taxonomic articulation-focused approach to dysarthria classification | NIH | National Institute on Deafness and Other Communication Disorders | 2022 to 2025 | $1,726,595 | August 17, 2022 | May 31, 2028 | MEFFERD, ANTJE | reporter.nih.gov |
| Residue-by-residue details of FUS protein phase separation and aggregation | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,694,269 | September 23, 2022 | August 31, 2026 | FAWZI, NICOLAS LUX | reporter.nih.gov |
| Determining stathmin-2 function and potential as a therapeutic target in ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $1,692,971 | April 1, 2020 | March 31, 2025 | CLEVELAND, DON W | reporter.nih.gov |
| Investigating Toxic Elements and Nanoparticles in ALS Etiology: A Geospatial and Toxicological Evaluation of Massachusetts ALS Registry Patients | NIH | National Institute of Environmental Health Sciences | 2022 to 2025 | $1,687,981 | September 19, 2022 | July 31, 2027 | STOMMEL, ELIJAH W | reporter.nih.gov |
| AI-assisted multimodal digital remote screening for bulbar ALS to support timely referral to SLP care | NIH | National Institute on Deafness and Other Communication Disorders | 2021 to 2025 | $1,676,959 | July 20, 2018 | July 31, 2030 | YUNUSOVA, YANA | reporter.nih.gov |
| Effects of TDP-43 Proteinopathy on Retrotransposon Activation and Cell-Type Specific Vulnerability in a Mammalian Model of Alzheimer's and Related Dementias | NIH | National Institute on Aging | 2023 to 2025 | $1,671,733 | December 1, 2022 | November 30, 2027 | SHER, ROGER B | reporter.nih.gov |
| In vivo modelling and therapy development for stathmin-2 loss in TDP-43 proteinopathies | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,648,874 | August 1, 2021 | July 31, 2026 | LAGIER-TOURENNE, CLOTILDE | reporter.nih.gov |
| Dysfunctional Astroglial Exosome to (motor) Neuron Axon Signaling in ALS | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,637,423 | February 1, 2022 | January 31, 2027 | YANG, YONGJIE | reporter.nih.gov |
| Cell-type-specific toxicity of C9orf72 repeat expansions in FTD and ALS | NIH | National Institute on Aging | 2021 to 2024 | $1,637,016 | September 15, 2020 | May 31, 2025 | JIANG, JIE | reporter.nih.gov |
| CHCHD10 Frontotemporal Dementia, Molecular Mechanisms and Therapeutic Strategies | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,635,738 | August 22, 2024 | July 31, 2029 | FUJITA, HIBIKI | reporter.nih.gov |
| Modeling the progression of SOD1-linked motor neuron disease | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,591,354 | December 15, 2015 | May 31, 2027 | CHAKRABARTY, PARAMITA | reporter.nih.gov |
| Stathmin-2 and TDP-43 neurodegeneration in Alzheimer’s and multi-etiology dementias | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,583,390 | April 1, 2021 | April 30, 2027 | JOSEPHS, KEITH A | reporter.nih.gov |
| Using Mitochondrial Ca2+ Uptake as a Therapeutic Target for ALS | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,580,278 | May 1, 2023 | April 30, 2027 | WEI-LAPIERRE, LAN | reporter.nih.gov |
| Investigating Motor Neuron Disease in Spinocerebellar Ataxia, Type1 | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,575,363 | September 1, 2023 | August 31, 2028 | ORENGO, JAMES P | reporter.nih.gov |
| Atypical TDP43 isoforrms driving neurodegeneration in FTD/ALS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,560,000 | December 1, 2019 | November 30, 2025 | BARMADA, SAMI | reporter.nih.gov |
| Defining TBK1-associated autophagy networks in neurons | NIH | National Institute on Aging | 2024 to 2025 | $1,557,479 | August 15, 2024 | April 30, 2029 | MORDES, DANIEL ADAM | reporter.nih.gov |
| Animal testing of RNA aptamers as ALS drug candidate | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,535,885 | June 15, 2022 | May 31, 2027 | NIU, LI | reporter.nih.gov |
| Double-stranded RNA in neuronal cell death in Alzheimer's and related neurodegenerative diseases | NIH | National Institute on Aging | 2024 to 2025 | $1,529,926 | July 1, 2024 | March 31, 2029 | LINK, CHRISTOPHER D. | reporter.nih.gov |
| Modulating an Astrocyte Hemichannel to Delay Spatial and Temporal Progression in ALS. | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,527,714 | July 1, 2020 | June 30, 2025 | MARAGAKIS, NICHOLAS J | reporter.nih.gov |
| Role of oligomeric TDP-43 aggregate intermediates in ALS and frontotemporal dementia | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,517,828 | February 1, 2020 | January 31, 2026 | AYALA, YUNA | reporter.nih.gov |
| PASK-regulated genes and proteins as therapeutic targets for ALS and FTD | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,516,783 | September 19, 2024 | July 31, 2029 | SCOLES, DANIEL R | reporter.nih.gov |
| Defining modifiers and mechanisms of RAN translation | NIH | National Institute on Aging | 2024 to 2025 | $1,516,148 | May 1, 2019 | April 30, 2028 | PUGLISI, JOSEPH D | reporter.nih.gov |
| Environmental risk factors linked to TDP-43 proteinopathies | NIH | National Institute on Aging | 2024 to 2025 | $1,507,263 | August 15, 2024 | April 30, 2029 | COHEN, TODD JONATHAN | reporter.nih.gov |
| A Chemical Footprinting Approach towards Poly-ADP-Ribosylation-regulated Biomolecular Condensation | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,502,609 | September 1, 2022 | November 30, 2026 | YU, YONGHAO | reporter.nih.gov |
| Development of a novel oral brain penetrant therapeutic for ALS disease | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $1,499,212 | June 15, 2025 | May 31, 2027 | LARSEN, GLENN | reporter.nih.gov |
| Multiplexed Quantification of the Protein Poly-ADP-Ribosylation Landscape in C9ORF72-ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,495,087 | May 1, 2024 | April 30, 2029 | YU, YONGHAO | reporter.nih.gov |
| Multimeric Peptide Copolymer Formulations for Targeted Drug Delivery to Treat Nervous System Disorders | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,450,737 | June 15, 2020 | May 31, 2026 | SELLERS, DREW L | reporter.nih.gov |
| Analysis of mRNP granule clearance, vacuolar RNA decay and TDP-43 turnover | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,449,492 | June 1, 2016 | May 31, 2027 | BUCHAN, JOHN ROSS | reporter.nih.gov |
| NAD+ metabolism and signaling in ALS models | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,449,180 | September 30, 2020 | August 31, 2026 | VARGAS, MARCELO R | reporter.nih.gov |
| LEGENNDS: Linking Epidemiology and GEnetics of Neurodevelopmental and Neurodegenerative Disorders Study | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $1,448,091 | May 1, 2023 | April 30, 2028 | LEE, BRIAN KANE | reporter.nih.gov |
| S-Nitrosylation-Dependent Pathological Spread of Abnormal Proteins in Frontotemporal Dementia and Lewy Body Dementia | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,431,052 | August 1, 2021 | July 31, 2027 | NAKAMURA, TOMOHIRO | reporter.nih.gov |
| Development of a CRISPR-Cas13 Gene Therapy for SOD1-Linked ALS | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,424,204 | February 1, 2022 | January 31, 2027 | GAJ, THOMAS | reporter.nih.gov |
| C9orf72 frontotemporal dementia (FTD) and amyotrophic lateral sclerosis(ALS): using patient cells and CRISPR to reveal therapeutic approaches | NIH | National Institute on Aging | 2024 to 2025 | $1,403,325 | May 1, 2021 | April 30, 2026 | CONKLIN, BRUCE R | reporter.nih.gov |
| Development of a topical tracer to detect TDP43 in ALS, LATE and FTD retinas for AI-powered disease insights | NIH | National Institute on Aging | 2025 | $1,388,697 | August 15, 2022 | May 31, 2027 | SARRAF, STELLA | reporter.nih.gov |
| Defining mechanisms of AAA+ disaggregases | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $1,366,630 | January 1, 2013 | May 31, 2025 | SHORTER, JAMES | reporter.nih.gov |
| Role of the TE-cGAS-STING pathway in C9orf72-ALS/FTD pathogenesis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,360,696 | September 18, 2024 | August 31, 2029 | TROTTI, DAVIDE | reporter.nih.gov |
| Relaxivity Contrast Imaging as Biomarker of Muscle Degeneration in ALS | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $1,314,058 | March 1, 2023 | November 30, 2025 | QUARLES, CHRISTOPHER CHAD | reporter.nih.gov |
| Deciphering the structural basis of repeat-associated non-AUG (RAN) translation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,288,272 | September 18, 2024 | August 31, 2029 | BRITO QUERIDO, JAILSON | reporter.nih.gov |
| Mechanisms of chimeric DPR production and toxicity in c9ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,283,766 | July 1, 2024 | April 30, 2029 | MCEACHIN, ZACHARY THOMAS | reporter.nih.gov |
| Regulation of axonal degeneration by the DLK kinase | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,275,489 | June 1, 2024 | May 31, 2027 | DIANTONIO, AARON | reporter.nih.gov |
| Molecular Phenotyping of Cortical Cell Types in ALS-Related Neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $1,258,538 | June 1, 2023 | May 31, 2027 | SCHMIDT, ERIC F | reporter.nih.gov |
| 3D in vitro model of genetic and sporadic FTD: accelerating novel therapeutic development | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $1,253,527 | May 9, 2025 | April 30, 2027 | GHAFFARI, LAYLA | reporter.nih.gov |
| Mechanistic studies and therapeutics for ALS/FTD linked to UBQLN2 mutations | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,242,686 | January 15, 2017 | January 31, 2027 | MONTEIRO, MERVYN J | reporter.nih.gov |
| Identifying T cell determinants of heritable Frontotemporal dementia | NIH | National Institute on Aging | 2024 to 2025 | $1,236,405 | April 1, 2024 | March 31, 2029 | BURBERRY, AARON | reporter.nih.gov |
| Neural Mechanisms of Empathy Loss in Frontotemporal Dementia | NIH | National Institute on Aging | 2024 to 2025 | $1,236,010 | May 1, 2024 | April 30, 2029 | YAO, WEI-DONG | reporter.nih.gov |
| Homeostatic Stabilization of Neural Function in Health and Disease | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $1,174,913 | December 15, 2024 | November 30, 2032 | DAVIS, GRAEME W | reporter.nih.gov |
| URIL tags for intracellular RNA tracking and RNP proximity labeling | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,154,022 | September 27, 2023 | June 30, 2027 | BONG, DENNIS | reporter.nih.gov |
| Social Connectedness in People with Amyotrophic Lateral Sclerosis: The Impact of Dysarthria, Immobility, and Psychosocial Factors | NIH | National Institute on Deafness and Other Communication Disorders | 2024 to 2025 | $1,145,123 | September 1, 2024 | June 30, 2029 | CONNAGHAN, KATHRYN PATRICIA | reporter.nih.gov |
| Expanding insights into FTD disease mechanisms | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $1,138,538 | December 15, 2024 | November 30, 2032 | PETRUCELLI, LEONARD | reporter.nih.gov |
| Innovating next generation technologies to define mechanisms of neurodegenerative disease and devise therapeutic strategies | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $1,136,484 | December 18, 2024 | November 30, 2032 | GITLER, AARON D. | reporter.nih.gov |
| Preservation of muscle function through Schwann cell regulation of motor unit expansion | NIH | National Institute on Aging | 2024 to 2025 | $1,130,661 | September 20, 2024 | May 31, 2029 | BROOKS, SUSAN V | reporter.nih.gov |
| Identifying mechanisms of neurofilament regulation and turnover in amyotrophic lateral sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,106,142 | September 1, 2024 | July 31, 2029 | LY, CINDY V | reporter.nih.gov |
| Understanding Frontotemporal Dementia Using Drosophila and iPSC Models | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $1,095,779 | April 15, 2017 | March 31, 2027 | GAO, FEN-BIAO | reporter.nih.gov |
| Early Respiratory Care in Amyotrophic Lateral Sclerosis Patients at High Risk for Respiratory Failure | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $981,842 | January 1, 2021 | June 30, 2026 | ACKRIVO, JASON | reporter.nih.gov |
| CRISPR-Cas9 editing in C9orf72 patient derived iPSC | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $961,200 | July 1, 2020 | June 30, 2025 | CLELLAND, CLAIRE | reporter.nih.gov |
| Unraveling the Aggregation of TDP43 Fragments Associated with ALS and FTD: Insights into Protein Quality Control Mechanisms and Cellular Vulnerability | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2025 | $934,383 | May 15, 2016 | July 31, 2028 | BROWER, CHRISTOPHER SCOTT | reporter.nih.gov |
| Connecting TDP-43 Pathology to the Molecular Profiles of Neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $879,816 | August 15, 2020 | July 31, 2025 | GALE HAMMELL, MOLLY | reporter.nih.gov |
| TDP43 Degradation by the Lysosomal Proteases in Amyotrophic Lateral Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $863,622 | July 1, 2022 | June 30, 2027 | SAMPOGNARO, PAUL JOSEPH | reporter.nih.gov |
| Viral-based Therapeutic Approaches for Reversal of ALS Pathology | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $854,698 | September 15, 2020 | June 30, 2025 | AMADO, DEFNE AUDREY | reporter.nih.gov |
| The functions of the zinc finger protein ZPR1 in R-loop metabolism and neurodegeneration. | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $823,812 | January 1, 2021 | December 31, 2027 | GANGWANI, LAXMAN DASS | reporter.nih.gov |
| Comprehensive Harmonization and Analysis of Case/Control Whole Genome Sequencing Data from the ALS/FTD Compute Project | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $817,388 | February 1, 2023 | July 31, 2028 | LANDERS, JOHN E | reporter.nih.gov |
| Generation and analysis of mouse models to define the roles of the ALS-associated factor Zfp106/ZNF106 in neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $799,743 | January 1, 2024 | December 31, 2028 | BLACK, BRIAN L | reporter.nih.gov |
| Age-related TDP-43 neuropathology: using disease-driving mechanisms to guide classification | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $790,914 | September 15, 2020 | March 31, 2026 | CYKOWSKI, MATTHEW DANIEL | reporter.nih.gov |
| C9orf72-mediated features transcriptomic signatures and translational studies for frontotemporal dementia and related disorders | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $788,248 | June 15, 2022 | May 31, 2027 | VAN BLITTERSWIJK, MARKA | reporter.nih.gov |
| Deciphering TDP-43 Proteinopathy: Unveiling the Consequences on Oligodendrocyte Dysfunction | NIH | National Institute on Aging | 2024 | $787,095 | June 15, 2024 | May 31, 2026 | PORTA ANTOLINEZ, SILVIA | reporter.nih.gov |
| Targeting STAU1 for TDP-43 proteinopathies | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $769,994 | August 15, 2022 | July 31, 2026 | SCOLES, DANIEL R | reporter.nih.gov |
| Elucidating the role of RNA oxidation on amyotrophic lateral sclerosis onset and progression | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $760,943 | December 1, 2021 | November 30, 2026 | CHAIM, ISAAC ALEXANDER | reporter.nih.gov |
| Exploring functional complexes and disease networks within human RNA-binding protein interactomes | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $747,792 | August 1, 2019 | June 30, 2025 | BRANNAN, KRISTOPHER | reporter.nih.gov |
| Mechanisms of nuclear pore complex homeostasis and injury in ALS/FTD and related neurodegenerative diseases | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $747,000 | July 15, 2021 | July 31, 2025 | COYNE, ALYSSA | reporter.nih.gov |
| Developing RNA Oligonucleotides to Mitigate Abberant FUS Phase Transition in FTD/ALS | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $741,000 | April 1, 2021 | March 31, 2026 | GUO, LIN | reporter.nih.gov |
| Identifying and understanding the role of repeat RNAs and RAN proteins in Alzheimer's disease | NIH | National Institute on Aging | 2023 to 2025 | $740,057 | July 1, 2023 | March 31, 2026 | NGUYEN, LIEN | reporter.nih.gov |
| Brainwide Computations Underlying Future Action Plans | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $739,529 | May 15, 2020 | April 30, 2026 | MACHADO, TIMOTHY ALOYSIUS | reporter.nih.gov |
| Regulation of ATAD3A in TDP43-associated ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $737,720 | July 1, 2025 | March 31, 2030 | QI, XIN | reporter.nih.gov |
| Loss of TDP-43 disrupts the prefrontal neural activity and circuitry: relevance for TDP-43 linked ADRD | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $736,565 | September 19, 2022 | August 31, 2027 | LI, YUN | reporter.nih.gov |
| Translation dysregulation in neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $707,634 | June 1, 2025 | May 31, 2027 | ZARNESCU, DANIELA C | reporter.nih.gov |
| Molecular effects of metformin, PKR and TBI on C9orf72 ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $705,919 | August 1, 2016 | August 31, 2027 | RANUM, LAURA P.W | reporter.nih.gov |
| Improving Shared Decision-Making Surrounding Dysphagia Management for Persons Diagnosed with Amyotrophic Lateral Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $699,482 | April 1, 2022 | March 31, 2027 | PERRY, BRIDGET J | reporter.nih.gov |
| Developing an Anti-proteotoxicity Therapy for Neurodegenerative Diseases | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $694,318 | September 17, 2024 | August 31, 2027 | ZHANG, TAO | reporter.nih.gov |
| Novel repeat associated non-AUG (RAN) proteins in sALS sFTD and SBMA: shared pathological features and unifying therapeutic opportunities | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $693,663 | July 1, 2022 | June 30, 2027 | RANUM, LAURA P.W | reporter.nih.gov |
| Metabolic Alteration in Presymptomatic and Symptomatic ALS Study (MAPS ALS Study) | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $688,905 | May 1, 2023 | April 30, 2028 | LEE, IKJAE | reporter.nih.gov |
| Defining the Role of Poly ADP-ribose in Biomolecular Condensation in ALS and FTLD | NIH | National Institute on Aging | 2024 | $654,638 | September 30, 2020 | August 31, 2025 | MYONG, SUA | reporter.nih.gov |
| Modulating miR-218 in human motor neurons using assembloids | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $652,806 | August 8, 2022 | October 10, 2024 | AMIN, NEAL DILIP | reporter.nih.gov |
| Effects of Re-expression of Motor Neuron Selector Transcription Factors on ALS Pathology | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $645,391 | December 1, 2024 | November 30, 2029 | WICHTERLE, HYNEK | reporter.nih.gov |
| TDP-43 LLPS and mitochondrial dysfunction in neurodegeneration | NIH | National Institute on Aging | 2025 | $638,682 | August 1, 2025 | May 31, 2030 | WANG, XINGLONG | reporter.nih.gov |
| Deubiquitinase USP19 in TDP-43 pathogenesis. | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $595,610 | May 1, 2022 | April 30, 2027 | KANG, DAVID E | reporter.nih.gov |
| Regulation of sphingolipid biosynthesis and motor neuron disease | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $592,233 | August 1, 2025 | June 30, 2030 | MOHASSEL, PAYAM | reporter.nih.gov |
| The role of m6A RNA methylation in C9ORF72-ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $582,989 | July 15, 2022 | April 30, 2027 | SUN, SHUYING | reporter.nih.gov |
| Novel role of mitochondrial carrier protein PSAP in regulation of both apoptosis and autophagy in ALS | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $580,385 | July 1, 2024 | June 30, 2025 | XU, XUEMIN | reporter.nih.gov |
| Brain aging and Alzheimer's related dementias: convergence onto retrotransposons and endogenous retroviruses | NIH | National Institute on Aging | 2025 | $567,909 | May 1, 2022 | April 30, 2027 | DUBNAU, JOSHUA T | reporter.nih.gov |
| Contributions of Endothelial RNA-binding Protein Dysregulation to Blood Brain Barrier Defects and Neurodegenerative Disease | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $544,285 | August 15, 2020 | January 31, 2026 | MURPHY, PATRICK ANDRIES | reporter.nih.gov |
| The pathogenic relationship between neuronal activity and C9orf72-linked neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $536,869 | September 15, 2020 | August 31, 2025 | HAEUSLER, AARON RAYMOND | reporter.nih.gov |
| Pathogenic mechanisms of KIF5A-associated ALS | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $532,381 | May 1, 2025 | April 30, 2030 | JIANG, JIE | reporter.nih.gov |
| Mechanistic insights of cortical hyperexcitability in ALS | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $506,074 | July 1, 2023 | June 30, 2025 | JIANG, JIE | reporter.nih.gov |
| High-throughput optimization of gene editing systems for treating Amyotrophic lateral sclerosis | NIH | National Institute on Aging | 2024 to 2025 | $500,000 | September 20, 2024 | May 31, 2027 | HUGHES, NICHOLAS | reporter.nih.gov |
| Precision Base Editing for the Treatment of Motor Neuron Diseases | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $490,531 | August 1, 2021 | December 31, 2026 | ARBAB, MANDANA | reporter.nih.gov |
| Investigating a novel vascular pathway that regulates neuronal survival | NIH | National Institute on Aging | 2025 | $480,710 | September 5, 2025 | May 31, 2030 | SOCKANATHAN, SHANTHINI | reporter.nih.gov |
| Implicating the major G-quadruplex helicase, DHX36, as a novel pathogenic modifier of C9ORF72 frontal temporal dementia | NIH | National Institute on Aging | 2024 | $475,516 | May 1, 2020 | July 31, 2027 | SMALDINO, PHILIP J | reporter.nih.gov |
| Mechanisms of disruption of axon transport of autophagic vesicles and lysosomes in C9orf72 ALS | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $465,774 | July 1, 2020 | June 30, 2026 | BERTH, SARAH HATCH | reporter.nih.gov |
| Mechanisms underlying TDP-43 dependent structural deficits in ALS muscles | NIH | National Institute on Aging | 2025 | $461,900 | May 1, 2025 | April 30, 2027 | ZARNESCU, DANIELA C | reporter.nih.gov |
| Lysosomal Regulation and Functions for TBK1 in Neurodegenerative Diseases | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $461,197 | June 9, 2025 | May 31, 2027 | FERGUSON, SHAWN | reporter.nih.gov |
| Role of Sarm1 in TBI-accentuated C9orf72 Frontotemporal Dementia | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $460,625 | February 1, 2023 | April 30, 2025 | HENNINGER, NILS | reporter.nih.gov |
| Cryo-EM Analysis of Ribosomal Defects in C9ORF72-Associated Frontotemporal Dementia and ALS | NIH | National Institute on Aging | 2023 to 2024 | $460,625 | August 15, 2023 | May 31, 2025 | GAO, FEN-BIAO | reporter.nih.gov |
| Mechanistic Investigation of Innate Immunity in a Drosophila Model of Frontotemporal Dementia | NIH | National Institute on Aging | 2024 | $460,625 | April 15, 2024 | March 31, 2026 | GAO, FEN-BIAO | reporter.nih.gov |
| Development of Mutant Specific Antisense Oligonucleotides for TARDBP and KIF5A as a Therapeutic for ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $460,625 | June 1, 2024 | May 31, 2026 | LANDERS, JOHN E | reporter.nih.gov |
| Investigating the Roles of the Deubiquitylation Pathway in TDP-43 Pathology in ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $460,625 | June 7, 2025 | May 31, 2027 | GAO, FEN-BIAO | reporter.nih.gov |
| Investigating the role of TDP-43 citrullination in ALS pathogenesis | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $460,625 | June 1, 2025 | May 31, 2027 | MASSI, FRANCESCA | reporter.nih.gov |
| Discovering targeted modulator of microglial activity as a candidate treatment for FTD and related dementias. | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $459,525 | July 2, 2024 | March 31, 2025 | JACKO, MARTIN | reporter.nih.gov |
| Cortical hyperexcitability in FTD and ALS: Exploring physiological biomarkers | NIH | National Institute on Aging | 2024 | $459,250 | June 1, 2024 | May 31, 2026 | DICKERSON, BRADFORD C | reporter.nih.gov |
| A Digital Biomarker for ALS - Pison Neural Biosensor | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $459,097 | June 12, 2025 | May 31, 2026 | BLACKWELL, MEGAN H. | reporter.nih.gov |
| The tRNA pool in C9-ALS/FTD | NIH | National Institute on Aging | 2023 to 2024 | $444,696 | April 1, 2023 | March 31, 2026 | HOU, YA-MING | reporter.nih.gov |
| Synthetic replicas of TDP-43 filaments associated with frontotemporal dementia | NIH | National Institute on Aging | 2025 | $442,750 | May 15, 2025 | April 30, 2027 | SUREWICZ, WITOLD K | reporter.nih.gov |
| Failure of Facilitation as a Biomarker in ALS | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $440,729 | July 11, 2023 | June 30, 2025 | TUNIK, EUGENE | reporter.nih.gov |
| Understanding dynamics of brain network in TDP-43 related neurodegeneration | NIH | National Institute on Aging | 2024 to 2025 | $439,061 | September 15, 2024 | June 30, 2027 | CHEN, RONG | reporter.nih.gov |
| Establishing iPSC-based models to investigate the mechanistic interaction between neurotrauma and ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $438,606 | August 1, 2025 | July 31, 2027 | KISKINIS, EVANGELOS | reporter.nih.gov |
| Cross validation of gene expression changes in C9orf72 FTD using Drosophila and human model systems | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $432,802 | June 1, 2025 | May 31, 2027 | ZARNESCU, DANIELA C | reporter.nih.gov |
| Molecular pathways linking frontotemporal dementia and circadian dysfunction | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $429,000 | March 7, 2024 | August 31, 2026 | KOH, KYUNGHEE | reporter.nih.gov |
| Delineating the role of Matrin-3 in driving aberrant liquid-liquid phase separation that underpins ALS/FTD | NIH | National Institute on Aging | 2023 to 2024 | $428,876 | January 1, 2023 | December 31, 2025 | JACKREL, MEREDITH E. | reporter.nih.gov |
| Peptide Nucleic Acid (PNA) Oligomers for Targeted Disruption of Biomolecular Condensates in ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $427,762 | September 9, 2024 | August 31, 2027 | ARMITAGE, BRUCE A. | reporter.nih.gov |
| Directly Converted Neurons as a Novel Cellular Model for ALS and FTD | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $427,625 | July 15, 2024 | June 30, 2026 | MILLER, TIMOTHY M. | reporter.nih.gov |
| Investigating surface signaling effectors of neurofilamenthyperphosphorylation: implications for neurodegenerative disease. | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $426,313 | August 1, 2025 | July 31, 2027 | SOCKANATHAN, SHANTHINI | reporter.nih.gov |
| The Role of Cyclin C in mediating neurodegenerative proteinopathies | NIH | National Institute on Aging | 2024 to 2025 | $424,450 | January 15, 2024 | December 31, 2026 | COOPER, KATRINA FRANCES | reporter.nih.gov |
| Regulation of paraspeckles by STAU1 in neurodegenerative disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $423,344 | April 1, 2023 | March 31, 2025 | SCOLES, DANIEL R | reporter.nih.gov |
| METTL3-mediated regulation of motor neuron function | NIH | National Institute on Aging | 2023 to 2024 | $421,714 | September 30, 2023 | January 31, 2025 | LOTTI, FRANCESCO | reporter.nih.gov |
| Defining the Mechanisms by Which Mutations in DNAJC7 Increase Susceptibility to ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $420,310 | January 18, 2023 | December 31, 2024 | KISKINIS, EVANGELOS | reporter.nih.gov |
| Probing Biomolecular Condensates in Live Cells using Microsecond-scale Single Molecule Rotational Diffusion Microscopy (µs-SiMRoD) | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $419,375 | September 18, 2024 | August 31, 2026 | MUSSER, SIEGFRIED M | reporter.nih.gov |
| Mechanisms of Neurodegeneration in KIF5A ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $416,340 | August 1, 2023 | July 31, 2028 | BRENT, JONATHAN ROBERT | reporter.nih.gov |
| Targeting Blood-CNS-Barrier in ALS via Apolipoprotein A1 | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $412,375 | May 15, 2023 | January 31, 2026 | GARBUZOVA-DAVIS, SVITLANA NICOLAI | reporter.nih.gov |
| A novel approach to restore functional TDP43 for the treatment of FTD and ALS | NIH | National Institute on Aging | 2025 | $404,058 | May 1, 2025 | April 30, 2027 | SACHS, JONATHAN N | reporter.nih.gov |
| Cell-based RNA degradation assay for C9ALS/FTD drug discovery | NIH | National Institute on Aging | 2024 | $392,116 | December 1, 2023 | November 30, 2025 | O'HANLON, RYAN | reporter.nih.gov |
| Unraveling the role of the molecular co-chaperone DNAJC7 in protein homeostasis and neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $391,140 | August 1, 2024 | June 30, 2029 | RAMANI, BISWARATHAN | reporter.nih.gov |
| Human-iPSC derived neuromuscular junctions as a model for neuromuscular diseases. | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $390,007 | September 8, 2023 | July 31, 2027 | MIRANDA, HELEN C | reporter.nih.gov |
| The Role of Proton-Mediated Signaling at the Neuromuscular Junction in ALS Models | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $387,525 | June 3, 2025 | May 31, 2027 | RENDEN, ROBERT B | reporter.nih.gov |
| Genetic analysis of UBQLN2-associated neurodegeneration in frontotemporal dementia | NIH | National Institute on Aging | 2024 | $386,449 | September 15, 2020 | August 31, 2025 | TIBBETTS, RANDAL SCOT | reporter.nih.gov |
| The translational potential of next-generation sporadic mouse and human models of ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $374,349 | December 24, 2024 | November 30, 2026 | COHEN, TODD JONATHAN | reporter.nih.gov |
| METTL3-mediated regulation of motor neuron function | NIH | National Institute on Aging | 2025 | $353,963 | September 30, 2023 | July 31, 2028 | LOTTI, FRANCESCO | reporter.nih.gov |
| Protein Structure, Dynamics, and Aggregation in Phase Separated Droplets | NIH | National Institute of General Medical Sciences | 2023 to 2024 | $328,554 | September 1, 2023 | February 1, 2025 | SERRANO, ARNALDO L | reporter.nih.gov |
| Bacterial triggers of neural inflammation. | NIH | National Institute on Aging | 2023 to 2024 | $322,000 | December 15, 2022 | November 30, 2024 | BURBERRY, AARON | reporter.nih.gov |
| Behavioral and Molecular Alterations in Drosophila with Modulated IK2/TBK1 Gene Expressions | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $265,620 | April 25, 2024 | March 31, 2027 | HE, FANG | reporter.nih.gov |
| Investigating Dysfunction of Neuroimmune-Related Processes in Models of ALS/FTD TDP-43 | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $251,250 | April 1, 2025 | March 31, 2027 | BOSCO, DARYL ANGELA | reporter.nih.gov |
| Development of a novel optical probe to study functional heterogeneity of individual neurotransmitter release sites at the neuromuscular junction | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $249,538 | March 7, 2024 | December 31, 2025 | BADAWI, YOMNA | reporter.nih.gov |
| Analysis of C9ORF72-associated poly (GR) interactions on BAF chromatin remodeling complex structure and function | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $236,668 | December 15, 2024 | November 30, 2029 | LOPEZ GONZALEZ, RODRIGO | reporter.nih.gov |
| Identifying Upper Motor Neuron Pathology and Molecular Signatures in the Amyotrophic Lateral Sclerosis (ALS) Motor Cortex | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $227,205 | December 15, 2024 | November 30, 2029 | DIAZ, FRANK | reporter.nih.gov |
| Understanding the relationship between cortical hyperexcitability and the progression of FTD/ALS pathology and behavioral deficits in mice | NIH | National Institute on Aging | 2024 to 2025 | $224,140 | September 1, 2024 | August 31, 2026 | ALGAMAL, MOUSTAFA | reporter.nih.gov |
| Retrograde transmission of pathogenic TDP-43 to the CNS | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $220,387 | December 1, 2021 | October 31, 2024 | LYNCH, EILEEN MARIE | reporter.nih.gov |
| Shared and disparate genomic features of TDP-43 proteinopathies | NIH | National Institute on Aging | 2022 to 2024 | $218,266 | August 19, 2022 | August 18, 2025 | SPENCER, BARBARA ELIZABETH | reporter.nih.gov |
| Single Cell Dissection of Cerebrovascular Dysfunction in Parkinson's Disease and Amyotrophic Lateral Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $213,430 | September 1, 2022 | August 31, 2025 | LINVILLE, RALEIGH MILLER | reporter.nih.gov |
| Defining the Role of DDX6 in Regulating FUS Condensates | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $176,189 | August 1, 2022 | January 31, 2026 | MEKONNEN, GEMECHU | reporter.nih.gov |
| Resilient Together-ALS (RT-ALS): A dyadic mind-body meaning intervention for people with ALS and their informal care-partners | NIH | National Center for Complementary & Integrative Health | 2025 | $170,604 | April 1, 2025 | March 31, 2030 | RUSH, CHRISTINA | reporter.nih.gov |
| A novel mouse model of TDP-43 Proteinopathy in FTLD-ALS: Elucidating the role of TDP-43 acetylation in neurodegeneration and proteostasis impairment | NIH | National Institute on Aging | 2021 to 2024 | $159,281 | July 1, 2021 | June 30, 2025 | NECARSULMER, JULIE CHRISTINE | reporter.nih.gov |
| Developing Digital Speech Biomarkers of Bulbar Disease Decline in Spanish-Speaking persons with Amyotrophic Lateral Sclerosis | NIH | National Institute of General Medical Sciences | 2025 | $149,695 | August 13, 2025 | July 31, 2029 | TABOR GRAY, LAUREN | reporter.nih.gov |
| Dissecting neuroinflammatory mechanisms in a model of progressive TDP-43 pathology | NIH | National Institute on Aging | 2024 to 2025 | $149,348 | February 1, 2024 | January 31, 2027 | O'CONNOR, JAMES T | reporter.nih.gov |
| A structurally suitable neck exoskeleton for amyotrophic lateral sclerosis | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 | $148,449 | August 1, 2024 | July 31, 2026 | ZHANG, HAOHAN | reporter.nih.gov |
| Cellular perturbations to enhance precise therapeutic genome editing to treat FTD/ALS | NIH | National Institute on Aging | 2023 to 2024 | $143,364 | April 1, 2023 | March 31, 2025 | MACKLIN, BRIA | reporter.nih.gov |
| The role of gasdermins in microglial activation and neurodegeneration in ALS/FTD | NIH | National Institute on Aging | 2023 to 2024 | $143,364 | September 30, 2023 | March 3, 2026 | GUNNER, GEORGIA | reporter.nih.gov |
| Clinicopathologic correlates of cognitive impairment in amyotrophic lateral sclerosis and frontotemporal dementia spectrum disorders (ALS-FTD) | NIH | National Institute on Aging | 2022 to 2024 | $135,085 | February 1, 2022 | June 30, 2024 | PETRESCU, JOANA | reporter.nih.gov |
| Developing RNA therapeutics for TDP-43 proteinopathy in ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $130,976 | September 1, 2022 | August 31, 2025 | COPLEY, KATIE ELIZABETH | reporter.nih.gov |
| Understanding the Genetic and Epigenetic Mechanisms in X-linked Dystonia Parkinsonism and Repeat Expansion Diseases | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $129,170 | August 1, 2025 | July 31, 2027 | MEJIA MAZA, ALAN | reporter.nih.gov |
| Advanced Base and Prime Editing Strategies to Correct Common ALS-causing SOD1 Mutations | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $124,246 | December 1, 2024 | November 30, 2026 | MEIJBOOM, KATHARINA E | reporter.nih.gov |
| Characterizing Vulnerable Cell Types in C9orf72-FTD | NIH | National Institute on Aging | 2022 to 2025 | $123,535 | January 1, 2023 | May 31, 2025 | DAI, DAVID | reporter.nih.gov |
| Determining the Mechanism of RAN Translation in C9orf72-Associated ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2024 | $122,538 | May 1, 2022 | April 30, 2025 | MILLER, SHANNON LYNNE | reporter.nih.gov |
| RNA Processing Misregulation in KIF5A ALS | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $121,554 | January 1, 2025 | December 31, 2025 | LE, PHUONG | reporter.nih.gov |
| Deciphering terminal selector functions in motor neurons: from worms to humans | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $121,230 | August 1, 2025 | July 31, 2026 | SMITH, JAYSON JAVELL | reporter.nih.gov |
| Understanding and Manipulating the Degradation of the C9orf72 Repeat Expansion RNA | NIH | National Institute on Aging | 2022 to 2024 | $121,129 | March 1, 2022 | February 28, 2025 | SHEHATA, SORAYA I | reporter.nih.gov |
| Engineering and evolving substrate-specific Hsp104 variants | NIH | National Institute of General Medical Sciences | 2021 to 2024 | $116,660 | December 1, 2021 | January 26, 2024 | RYAN, JEREMY | reporter.nih.gov |
| Investigating the Role of MS4As in Amyotrophic Lateral Sclerosis | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2025 | $107,884 | September 1, 2023 | August 31, 2026 | HILLER, ABIGAIL JEAN | reporter.nih.gov |
| Synaptic TDP43 in the Adult Mouse Brain | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $100,512 | September 1, 2024 | August 31, 2026 | WASSERLEIN, ELIZABETH MORAN | reporter.nih.gov |
| Assessing the Contribution of Cortical Hyperactivity to ALS Phenotypes in a Human-Derived Motor System | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $98,512 | April 1, 2024 | March 31, 2027 | PIO, TAYLOR | reporter.nih.gov |
| From Speech Function to Communicative Participation in Dysarthria | NIH | National Institute on Deafness and Other Communication Disorders | 2023 to 2024 | $94,275 | June 1, 2023 | August 22, 2024 | HAENSSLER, ABIGAIL | reporter.nih.gov |
| The Role of Neutrophil Heterogeneity and Molecular Mechanisms in Driving ALS | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $86,666 | July 1, 2024 | June 30, 2027 | BAIRD, LILLIA | reporter.nih.gov |
| Identifying the function of alternatively spliced TDP43 isoforms and contribution to disease | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $83,462 | August 1, 2023 | July 31, 2026 | DYKSTRA, MEGAN | reporter.nih.gov |
| Robust and scalable Bayesian analysis tools for single cell CRISPR screens with sequencing- and imaging-based readouts | NIH | National Human Genome Research Institute | 2024 to 2025 | $80,685 | July 1, 2024 | June 30, 2027 | BLAINE, LOGAN | reporter.nih.gov |
| Multispectral Imaging of Neurons and Astrocytes: Revealing Spatiotemporal Organelle Phenotypes in Health and Neurodegeneration | NIH | National Institute on Aging | 2023 to 2024 | $79,556 | June 15, 2023 | June 14, 2026 | RHOADS, SHANNON | reporter.nih.gov |
| Role of Astrocytic HTRA1 Signaling in Blood-Brain Barrier (BBB) Maintenance | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $78,646 | January 12, 2022 | July 31, 2029 | JAHAN, NAZNIN | reporter.nih.gov |
| Defining the mechanisms by which mutations in DNAJC7 increase susceptibility to ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2023 to 2024 | $77,317 | September 1, 2023 | January 24, 2025 | FLEMING, ANDREW | reporter.nih.gov |
| Exploring TMEM106B in Neurodegeneration: Protein Interaction and Fibril-induced Neurotoxicity | NIH | National Institute on Aging | 2024 | $52,082 | September 1, 2024 | August 31, 2025 | TILAHUN, KEDAMAWIT | reporter.nih.gov |
| The role of OPC-microglia interactions in TDP-43-related neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $49,738 | July 1, 2025 | June 30, 2026 | PALLEGAR, PRAVEEN | reporter.nih.gov |
| The role of microglia in TRPV4 mediated neurodegeneration | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $49,538 | June 2, 2025 | December 1, 2026 | ALEVY, JONATHAN | reporter.nih.gov |
| Molecular mechanism underlying FUS regulation under transcriptional and DNA damage stress | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $49,538 | September 1, 2025 | September 30, 2026 | YUAN, XINCHENG | reporter.nih.gov |
| Characterizing clearance mechanisms of TDP-43 and disease associated isoforms | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $49,538 | August 1, 2025 | July 31, 2027 | MARMORALE, LUCAS JAKE | reporter.nih.gov |
| Unveil the functional role of RNA spatial localization in neuronal function and neurodegeneration by developing novel CRISPR-TO tools | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $49,538 | September 30, 2025 | August 29, 2028 | FU, MAYLIN | reporter.nih.gov |
| Targeting transcription and translation of the antisense CCCCGG repeat expansion in C9ORF72 ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2024 | $48,974 | January 1, 2025 | December 31, 2026 | ANTONOPOULOS, MIRA N | reporter.nih.gov |
| Endothelial-Derived Signatures of Neurodegenerative Progression | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $46,415 | August 1, 2025 | July 31, 2029 | DEROSA, SAMANTHA GRACE | reporter.nih.gov |
| Microglia- Astrocyte Crosstalk in Cortical Neurodegeneration of C9orf72 ALS/FTD | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $45,724 | August 13, 2025 | February 13, 2028 | ONDATJE, BRIANA | reporter.nih.gov |
| Cryptococcal Nanotherapy: Engineering a Novel Fungus-Based Platform for Improved Drug Delivery to the Central Nervous System | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $44,466 | January 1, 2026 | December 31, 2028 | SMITH, CLINTON | reporter.nih.gov |
| Linking RNA methylation and TDP43 pathology in ALS/FTD models | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $43,631 | September 1, 2025 | August 31, 2028 | HSIEH, CAROLINE Y. | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Massachusetts General Hospital | Boston, MA | 9 | $117.7 million | 0 | $0 |
| ST. Joseph's Hospital and Medical Center | Phoenix, AZ | 3 | $55.5 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 14 | $55.3 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 21 | $40.8 million | 0 | $0 |
| Mayo Clinic Jacksonville | Jacksonville, FL | 7 | $25.4 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 15 | $25.1 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 15 | $24.2 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 17 | $21.5 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 8 | $17.3 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 2 | $13.8 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 2 | $12.5 million | 0 | $0 |
| Stanford University | Stanford, CA | 6 | $12.1 million | 0 | $0 |
| Washington University | Saint Louis, MO | 10 | $11.8 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 1 | $11.3 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 3 | $9.8 million | 0 | $0 |
| Yale University | New Haven, CT | 4 | $9.4 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 7 | $8.9 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 6 | $8.1 million | 0 | $0 |
| Brown University | Providence, RI | 3 | $8.1 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 2 | $7.7 million | 0 | $0 |
| Fox Chase Chemical Diversity Center, INC | Doylestown, PA | 1 | $7.4 million | 0 | $0 |
| Carnegie Mellon University | Pittsburgh, PA | 2 | $6.2 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 7 | $5.7 million | 0 | $0 |
| Acurastem, Inc. | Pasadena, CA | 2 | $5.6 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 2 | $5.5 million | 0 | $0 |
| University of Florida | Gainesville, FL | 6 | $5.4 million | 0 | $0 |
| New York Genome Center | New York, NY | 2 | $5.3 million | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 3 | $5.3 million | 0 | $0 |
| Wright State University | Dayton, OH | 2 | $4.4 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 4 | $4.3 million | 0 | $0 |
| Emory University | Atlanta, GA | 6 | $4.1 million | 0 | $0 |
| Columbia University | New York, NY | 1 | $4 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 2 | $3.9 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 1 | $3.8 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 3 | $3.7 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 1 | $3.7 million | 0 | $0 |
| Jackson Laboratory | Bar Harbor, ME | 1 | $3.6 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 5 | $3.5 million | 0 | $0 |
| University of Colorado at Boulder | Boulder, CO | 3 | $3.5 million | 0 | $0 |
| Winifred Masterson Burke Med Res Inst | White Plains, NY | 1 | $3.4 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 1 | $3.3 million | 0 | $0 |
| University of Chicago | Chicago, IL | 3 | $3.1 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 1 | $3.1 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 4 | $2.9 million | 0 | $0 |
| University of Missouri-Columbia | Columbia, MO | 2 | $2.7 million | 0 | $0 |
| Seattle Inst for Biomedical/clinical Res | Seattle, WA | 1 | $2.6 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 2 | $2.4 million | 0 | $0 |
| Board of Regents, NSHE, obo University of Nevada, Reno | Reno, NV | 2 | $2.3 million | 0 | $0 |
| Celdara Medical, LLC | Lebanon, NH | 1 | $2.3 million | 0 | $0 |
| Modality.ai , INC | San Francisco, CA | 1 | $2.3 million | 0 | $0 |
| Neurodex INC | Arlington, MA | 1 | $2.1 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 4 | $2.1 million | 0 | $0 |
| University of California-Riverside | Riverside, CA | 1 | $2.1 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 2 | $2 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 1 | $2 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 1 | $2 million | 0 | $0 |
| MGH Institute of Health Professions | Charlestown, MA | 3 | $1.9 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 1 | $1.9 million | 0 | $0 |
| University of Texas at Arlington | Arlington, TX | 1 | $1.9 million | 0 | $0 |
| University of Rhode Island | Kingston, RI | 1 | $1.9 million | 0 | $0 |
| University of South Carolina at Columbia | Columbia, SC | 1 | $1.9 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 1 | $1.9 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 1 | $1.7 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 1 | $1.7 million | 0 | $0 |
| Dartmouth-Hitchcock Clinic | Lebanon, NH | 1 | $1.7 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 2 | $1.7 million | 0 | $0 |
| Sunnybrook Research Institute | Toronto | 1 | $1.7 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 1 | $1.6 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 1 | $1.6 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 2 | $1.6 million | 0 | $0 |
| Pennsylvania State Univ Hershey Med CTR | Hershey, PA | 3 | $1.6 million | 0 | $0 |
| J. David Gladstone Institutes | San Francisco, CA | 2 | $1.5 million | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 2 | $1.5 million | 0 | $0 |
| SUNY at Albany | Albany, NY | 1 | $1.5 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 1 | $1.5 million | 0 | $0 |
| Aquinnah Pharmaceuticals, Inc. | Newton, MA | 1 | $1.5 million | 0 | $0 |
| University of Washington | Seattle, WA | 1 | $1.5 million | 0 | $0 |
| Drexel University | Philadelphia, PA | 1 | $1.4 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 1 | $1.4 million | 0 | $0 |
| Amydis Diagnostics, Inc. | La Jolla, CA | 1 | $1.4 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 1 | $1.3 million | 0 | $0 |
| Rockefeller University | New York, NY | 1 | $1.3 million | 0 | $0 |
| Synapticure, Inc. | Kenilworth, IL | 1 | $1.3 million | 0 | $0 |
| Upstate Medical University | Syracuse, NY | 1 | $1.2 million | 0 | $0 |
| Ohio State University | Columbus, OH | 1 | $1.2 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 2 | $1.1 million | 0 | $0 |
| Texas Woman's University | Denton, TX | 1 | $934,383 | 0 | $0 |
| University of Wyoming | Laramie, WY | 1 | $736,565 | 0 | $0 |
| Rezigene, LLC | Baltimore, MD | 1 | $694,318 | 0 | $0 |
| University of Connecticut SCH of Med/dnt | Farmington, CT | 2 | $590,700 | 0 | $0 |
| University of Texas of the Permian Basin | Odessa, TX | 1 | $580,385 | 0 | $0 |
| Acrobat Genomics, Inc. | Foster City, CA | 1 | $500,000 | 0 | $0 |
| Ball State University | Muncie, IN | 1 | $475,516 | 0 | $0 |
| Aperture Therapeutics, Inc. | San Carlos, CA | 1 | $459,525 | 0 | $0 |
| Pison Technology, Inc. | Boston, MA | 1 | $459,097 | 0 | $0 |
| Northeastern University | Boston, MA | 1 | $440,729 | 0 | $0 |
| Rowan University School/osteopathic Med | Stratford, NJ | 1 | $424,450 | 0 | $0 |
| Texas A&m University Health Science CTR | College Station, TX | 1 | $419,375 | 0 | $0 |
| University of South Florida | Tampa, FL | 1 | $412,375 | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 1 | $404,058 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 216 | $226,255,953 | 0 | $0 |
| 2024 | 226 | $191,465,227 | 0 | $0 |
| 2023 | 163 | $159,628,498 | 0 | $0 |
| 2022 | 106 | $61,150,961 | 0 | $0 |
| 2021 | 73 | $45,785,974 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.